Update on gut microbiota in cardiovascular diseases

Buyun Qian; Kaiyu Zhang; Yuan Li; Kangyun Sun

doi:10.3389/fcimb.2022.1059349

Update on gut microbiota in cardiovascular diseases

Front Cell Infect Microbiol. 2022 Nov 10:12:1059349. doi: 10.3389/fcimb.2022.1059349. eCollection 2022.

Authors

Buyun Qian¹, Kaiyu Zhang¹, Yuan Li¹, Kangyun Sun¹

Affiliation

¹ Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Jiangsu, Suzhou, China.

Abstract

In recent years, due to the development and widespread utilization of metagenomic sequencing and metabolomics, the relationship between gut microbiota and human cardiovascular diseases (CVDs) has received extensive attention. A growing number of studies have shown a strong relationship between gut microbiota and CVDs, such as coronary atherosclerosis, hypertension (HTN) and heart failure (HF). It has also been revealed that intestinal flora-related metabolites, such as trimethylamine-N-oxide (TMAO), short-chain fatty acids (SCFA) and bile acids (BAs), are also related to the development, prevention, treatment and prognosis of CVDs. In this review, we presented and summarized the recent findings on the relationship between gut microbiota and CVDs, and concluded several currently known gut microbiota-related metabolites and the occurrence and development of CVDs.

Keywords: association; cardiovascular diseases (CVDs); gut microbiota; metabolites; therapies.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Bile Acids and Salts
Cardiovascular Diseases*
Gastrointestinal Microbiome*
Heart Failure*
Humans
Hypertension*

Substances

Bile Acids and Salts